Vitrification Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Specimen (Oocytes (Devices, Kits & Consumables), Embryo (Devices, Kits & Consumables), Sperm), By End-use (IVF Clinics, Biobanks), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 9.82 Billion
CAGR (2026-2031)	15.61%
Fastest Growing Segment	Biobanks
Largest Market	North America
Market Size (2031)	USD 23.45 Billion

Market Overview

The Global Vitrification Market will grow from USD 9.82 Billion in 2025 to USD 23.45 Billion by 2031 at a 15.61% CAGR. The Global Vitrification Market encompasses a cryopreservation technology that employs ultra-rapid cooling and high concentrations of cryoprotectants to solidify reproductive cells into a glass-like state, effectively preventing the formation of damaging ice crystals. The primary drivers fueling market expansion include the rising global prevalence of infertility and the increasing trend of delayed parenthood, which has spurred demand for oocyte and embryo banking. Furthermore, the superior post-thaw survival and pregnancy rates offered by vitrification compared to traditional slow-freezing methods have made it the preferred standard in assisted reproductive technology clinics worldwide.

Despite these strong growth indicators, the market faces a significant challenge regarding the high financial burden of procedures and the lack of standardized insurance reimbursement in many regions, which restricts patient accessibility. Statistical evidence highlights the continued adoption of these services despite such barriers. According to the Human Fertilisation and Embryology Authority, in 2025, data revealed that frozen embryo transfer cycles in the United Kingdom had increased by 24% over the preceding four-year reporting period, illustrating the dominant shift towards cryopreservation in fertility treatments.

Key Market Drivers

Rising global prevalence of infertility and the corresponding escalation in demand for Assisted Reproductive Technologies (ART) are the foremost drivers propelling the vitrification market. As demographic shifts lead to delayed family building, the window for natural conception narrows, necessitating advanced interventions to secure future reproductive potential. This trend is substantiated by the United Nations, which reported in May 2025 that the global fertility rate had declined to 2.2 births per woman in 2024, a statistic that underscores the critical urgency for effective preservation solutions. Consequently, fertility clinics are increasingly relying on vitrification for its superior survival rates compared to slow freezing, directly boosting the volume of cryopreservation procedures and the associated consumption of specialized media and devices.

Concurrently, the market is experiencing significant expansion due to the rising social acceptance of elective egg freezing, often supported by expanding corporate reimbursement policies and shifting career priorities. This surge in "social freezing" is clearly reflected in recent clinical activity; according to the Society for Assisted Reproductive Technology (SART), in 2025, data revealed that 39,269 oocyte banking cycles for fertility preservation were performed in the United States during the 2023 reporting year. This growing volume of preservation cycles underpins the broader financial health of the sector. Reflecting this robust demand for procedure-related products, Vitrolife Group announced in March 2025 that its sales of consumables increased by 10% in local currencies for the full year 2024.

Download Free Sample Report

Key Market Challenges

The high financial burden of procedures and the lack of standardized insurance reimbursement act as significant restraints on the growth of the Global Vitrification Market. While the clinical benefits of vitrification are well-established, the technology involves complex laboratory protocols and specialized storage requirements that drive up operational costs. In many regions, fertility preservation is categorized as an elective service rather than a medical necessity, forcing patients to shoulder the entire financial weight out-of-pocket. This economic barrier limits the addressable market to high-income demographics and prevents widespread adoption among the broader population that requires these services. Consequently, clinics face restricted patient volume growth, as the prohibitive cost of entry deters a vast segment of potential clients from initiating treatment.

This financial challenge is quantitatively supported by recent industry findings regarding the cost of care. According to the American Society for Reproductive Medicine, in 2024, the average cost of a single in vitro fertilization cycle in the United States ranged between $12,000 and $15,000, excluding the substantial expense of necessary medications. Such high expenditures, often unaccompanied by adequate insurance support, directly reduce the demand for vitrification services, thereby hampering the market's ability to reach its full potential globally.

Key Market Trends

Accelerated adoption of automated vitrification platforms is transforming the market by addressing the critical need for standardization and reproducibility in cryopreservation procedures. Unlike manual techniques, which are subject to inter-operator variability, automated systems deliver precise control over cooling rates and cryoprotectant exposure, thereby significantly reducing the risk of ice crystal formation and improving specimen safety. This industrial shift toward high-tech hardware solutions is quantitatively demonstrated by recent financial performance in the sector. According to Vitrolife Group, January 2025, in the 'Fourth Quarter and Full Year Report 2024', sales within the Technologies business area increased by 16% in local currencies, underscoring the rapid uptake of advanced equipment by clinics aiming to optimize laboratory workflows.

Integration of artificial intelligence for process optimization is concurrently enhancing the efficacy of vitrification through predictive analytics and non-invasive assessment tools. Machine learning algorithms are now being utilized to evaluate oocyte and embryo quality prior to freezing, allowing clinicians to customize protocols based on specific morphological biomarkers that predict post-thaw survival. This data-driven approach maximizes the potential for successful pregnancy while minimizing the number of cycles required for patients. According to the Journal of IVF-Worldwide, May 2025, in the article 'Global Trends in the Use of Artificial Intelligence in Reproductive Medicine', a survey found that the usage of AI tools among fertility specialists had risen to approximately 53% by 2025, confirming the technology's growing role in refining preservation strategies.

Segmental Insights

The Biobanks segment currently represents the fastest-growing category within the Global Vitrification Market, primarily driven by the expanding demand for long-term preservation of biological specimens. This rapid growth is fueled by the widespread adoption of vitrification, which prevents ice crystal formation and ensures superior viability for sensitive samples such as oocytes, embryos, and stem cells compared to traditional freezing methods. Furthermore, biobanks are increasingly vital for maintaining comprehensive donor databases, thereby supporting the rising reliance on third-party reproduction and fertility preservation services. As individuals seek to secure reproductive options for the future, biobanks provide the essential infrastructure for high-quality specimen management.

Regional Insights

North America maintains a dominant position in the global vitrification market due to the widespread adoption of assisted reproductive technologies across the United States and Canada. The region experiences high demand for these services because of rising infertility rates and a cultural shift toward delayed childbearing. This growth is further supported by established healthcare infrastructure and favorable guidelines from the American Society for Reproductive Medicine that endorse cryopreservation techniques. Additionally, the concentrated presence of key medical device manufacturers facilitates the accessibility of essential vitrification tools and consumables, thereby reinforcing the regional market leadership.

Recent Developments

• In June 2025, Kitazato announced the global launch of a new ultra-fast vitrification medium, which was distinguished as the first product in its category to receive MDR CE marking. The new protocol was engineered to reduce the vitrification procedure time to approximately two minutes, significantly optimizing laboratory workflow. By minimizing the duration of exposure to cryoprotectants, the solution aims to reduce osmotic and chemical stress on oocytes, thereby potentially enhancing post-thaw viability. This product launch reinforced Kitazato’s position in the market by offering a clinically validated, time-efficient solution that complies with rigorous European safety standards.
• In May 2025, Overture Life received regulatory clearance from the National Health Surveillance Agency (ANVISA) in Brazil to commercialize its DaVitri system, an automated device designed for the vitrification of human oocytes. This approval classified the platform as a Class I medical device, facilitating its entry into the largest market in Latin America. The system was developed to standardize the critical freezing step in IVF procedures, aiming to eliminate the variability inherent in manual techniques. By automating the dispensing and aspiration of fluids, the device seeks to improve the consistency of cryopreservation outcomes and operational efficiency in fertility clinics.
• In July 2024, TMRW Life Sciences announced the successful closing of a Series D equity financing round, securing over $28 million to advance its automated cryostorage solutions. The investment was led by a prominent life sciences venture capital firm and supported by returning investors. The funds were allocated to meet the escalating demand from fertility clinics for the company’s FDA-cleared platform, which automates the identification, management, and storage of frozen specimens. This financial milestone highlighted the industry's pivot toward replacing manual cryogenic tanks with robotic, digital systems to enhance the security and accuracy of vitrification inventories.
• In May 2024, Vitrolife AB completed the acquisition of eFertility, a health technology company specializing in digital practice management and witnessing software for IVF clinics. The transaction included an initial purchase price of €9.6 million. This strategic expansion allowed Vitrolife to integrate advanced digital tracking capabilities into its reproductive health platform, ensuring greater safety and traceability for vitrified reproductive specimens. By incorporating this technology, the company aimed to create a more seamless, end-to-end workflow for fertility laboratories, addressing the growing market demand for digitalisation and standardized risk management in the handling of frozen eggs and embryos.

Key Market Players

• Vitrolife Inc.
• Genea Biomedx inc.
• NidaCon International AB
• Minitube International
• IMV Technologies Group
• The Cooper Companies, Inc.
• FUJIFILM Corporation
• Biotech, Inc.
• Kitazato Corporation
• Shenzhen VitaVitro BiotechAGEN N.V.

By Specimen	By End-use	By Region
Oocytes (Devices Kits & Consumables) Embryo (Devices Kits & Consumables) Sperm	IVF Clinics Biobanks	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Vitrification Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Vitrification Market, By Specimen:

• Oocytes (Devices
• Kits & Consumables)
• Embryo (Devices
• Kits & Consumables)
• Sperm

• Vitrification Market, By End-use:

• IVF Clinics
• Biobanks

• Vitrification Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE